PCI Pharma Services Executive and Leadership Team

Tom DeWeerdt, the Chief Financial Officer at PCI Pharma Services, manages the fiscal health and capital allocation strategies for the entire organization. Overseeing financial planning, reporting, and risk management, the Chief Financial Officer ensures the company maintains the necessary resources to support global expansion and infrastructure investment. This leadership role involves collaborating with executive peers to evaluate the profitability of clinical trial services and manufacturing projects. By implementing robust financial controls, Tom DeWeerdt directly impacts the long-term sustainability of the business model. Ultimately, DeWeerdt drives value creation by optimizing cost structures and securing the financial stability required to support the complex, high-stakes requirements of the global pharmaceutical market, ensuring consistent growth across all international business units.

Brad Payne, the Chief Operating Officer at PCI Pharma Services, directs all internal operational workflows and global manufacturing efficiency. Overseeing the integration of analytical services and commercial packaging, the Chief Operating Officer ensures seamless execution across North American and European facilities. This leadership role involves optimizing supply chain management to meet complex pharmaceutical demands while maintaining strict regulatory compliance. By streamlining production processes, Brad Payne directly impacts the scalability of clinical trial supply operations. Ultimately, Payne secures operational excellence by aligning manufacturing output with the evolving needs of the global healthcare industry, ensuring that every project meets the highest standards of precision and reliability required for successful drug development and commercial distribution.

Laila Rubi, the Chief Operating Officer, Clinical Quality Documents at PCI Pharma Services, architects the framework for clinical documentation and regulatory compliance standards. Overseeing the integrity of quality systems, the Chief Operating Officer, Clinical Quality Documents ensures that all clinical trial data remains accurate and audit-ready. This leadership role involves coordinating with global regulatory bodies to maintain certifications across diverse pharmaceutical markets. By standardizing documentation protocols, Laila Rubi directly impacts the speed and reliability of clinical trial supply delivery. Ultimately, Rubi secures the company's reputation for excellence by enforcing rigorous quality controls that protect patient safety and facilitate the successful progression of drug development programs, ensuring that every document meets the stringent requirements of the global healthcare sector.

Ann Hudson, the Chief Operating Officer, Clinical Quality Documents at PCI Pharma Services, manages the strategic implementation of quality assurance programs for clinical trial documentation. Overseeing the technical review processes, the Chief Operating Officer, Clinical Quality Documents ensures that all operational outputs align with international quality benchmarks. This leadership role involves refining internal workflows to enhance the efficiency of document management systems during complex clinical trials. By fostering a culture of continuous improvement, Ann Hudson directly impacts the precision of the company's clinical trial services. Ultimately, Hudson secures operational compliance by mitigating risks associated with data management, ensuring that all pharmaceutical partners receive reliable, high-quality support throughout the critical phases of drug development and global clinical research.

Halley Liu, the President at PCI Pharma Services, defines the overarching corporate strategy and market positioning for the entire organization. Overseeing the alignment of diverse service lines, the President ensures that analytical services, formulation development, and distribution capabilities function as a cohesive unit. This leadership role involves driving long-term growth initiatives and expanding the company's footprint in the global healthcare market. By fostering innovation across all departments, Halley Liu directly impacts the competitive advantage of the firm. Ultimately, Liu secures the company's future by cultivating strategic partnerships and ensuring that the organization remains at the forefront of pharmaceutical manufacturing and supply chain solutions, consistently delivering value to clients through integrated, full-service support across international regions.

Brian Keesee, the President, Clinical Trial Services at PCI Pharma Services, directs the strategy and execution of all clinical trial supply operations. Overseeing the end-to-end management of clinical materials, the President, Clinical Trial Services ensures that global trials receive timely and accurate support. This leadership role involves coordinating with pharmaceutical clients to navigate the complexities of clinical logistics and storage requirements. By optimizing the supply chain for clinical research, Brian Keesee directly impacts the success of drug development timelines. Ultimately, Keesee secures the company's position as a leader in clinical trial support by implementing scalable solutions that address the unique challenges of global research, ensuring that every trial receives the necessary resources to achieve critical milestones.

Michelle Logan, the President, Development & Manufacturing at PCI Pharma Services, leads the strategic direction of formulation development and commercial manufacturing operations. Overseeing the technical teams responsible for drug product creation, the President, Development & Manufacturing ensures that all manufacturing processes meet the highest quality standards. This leadership role involves scaling production capabilities to support the commercialization of new pharmaceutical products. By integrating advanced manufacturing technologies, Michelle Logan directly impacts the efficiency and output of the company's production facilities. Ultimately, Logan secures the company's market impact by delivering reliable, high-quality manufacturing services that enable pharmaceutical partners to bring life-saving treatments to market, ensuring that all development projects transition smoothly from initial formulation to full-scale commercial production.